DHEA and Pregnenolone Pathway Genetics: What Your DNA Reveals

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

Most hormone conversations start downstream — testosterone levels, aromatization, receptor sensitivity, DHT. But testosterone doesn't appear from nowhere. It is synthesized through a multi-step enzymatic cascade that begins with cholesterol and flows through two upstream steroid precursors: pregnenolone and DHEA (dehydroepiandrosterone). These molecules sit above testosterone in the steroid hierarchy, feeding the entire androgen-estrogen system. The genetic variants governing how efficiently your body makes, routes, and stores these precursors are the upstream source code for everything that happens downstream — and they're the layer of hormone genetics most androgen-pathway panels never reach.

The Steroid Cascade: From Cholesterol to DHEA

Every steroid hormone in the human body — testosterone, estradiol, cortisol, progesterone, aldosterone — originates from a single enzymatic conversion: cholesterol to pregnenolone, catalyzed by CYP11A1 (cytochrome P450 side-chain cleavage enzyme) in the inner mitochondrial membrane of adrenal cells. This is the rate-limiting gateway step of all steroid synthesis. The entire downstream cascade depends on how efficiently CYP11A1 can perform this conversion.

From pregnenolone, the steroid cascade splits into two major branches:

The Δ5 pathway — pregnenolone is converted by CYP17A1 (17α-hydroxylase/17,20-lyase) through 17-OH-pregnenolone to DHEA, then by HSD3B (3-beta-hydroxysteroid dehydrogenase) to androstenedione, and onward to testosterone and estrogens.

The Δ4 pathway — pregnenolone is converted by HSD3B to progesterone, then routed toward cortisol, aldosterone, or androstenedione depending on which adrenal enzyme machinery is most active at the time.

DHEA is the primary adrenal androgen and the most abundant circulating steroid in the body by concentration. Most circulating DHEA is rapidly sulfated to DHEA-S by SULT2A1 (sulfotransferase 2A1) for stable storage and transport, then de-sulfated at peripheral tissues for local conversion to androgens and estrogens as needed. The PlexusDx Precision Peptide Genetic Test analyzes the variants governing this cascade as part of 14 pathways, 49 peptides, and 150+ genetic insights.

Key Genes That Shape DHEA and Pregnenolone Production

CYP11A1 — the gateway enzyme that converts cholesterol to pregnenolone, setting the maximum capacity of the entire steroid precursor pool. CYP11A1 variants affect the rate of this first conversion, with functional polymorphisms associated with differences in adrenal steroidogenesis capacity across populations. A man with reduced CYP11A1 efficiency starts with a smaller pregnenolone pool that every downstream steroid hormone — including testosterone, cortisol, and estradiol — must draw from.

CYP17A1 — the bifunctional enzyme that drives DHEA production through two successive reactions: 17α-hydroxylase activity converts pregnenolone to 17-OH-pregnenolone, and then 17,20-lyase activity cleaves it to DHEA. These two activities can be independently affected by CYP17A1 variants — particularly the 17,20-lyase step, which specifically determines how much steroid flux is routed through DHEA rather than diverted toward progesterone and glucocorticoids. CYP17A1 is the primary genetic determinant of adrenal DHEA output, making it the most functionally consequential gene in this upstream pathway.

HSD3B / HSD3B2 — 3-beta-hydroxysteroid dehydrogenase converts DHEA to androstenedione and pregnenolone to progesterone. HSD3B2 is expressed in adrenal and gonadal tissues and governs how much DHEA is metabolized further toward active androgens versus retained in the DHEA precursor pool. HSD3B2 variants affecting enzymatic efficiency shift this balance, influencing how productively DHEA is utilized for downstream testosterone synthesis.

SULT2A1 — sulfotransferase 2A1 sulfates DHEA to its storage form, DHEA-S. SULT2A1 variants influence the DHEA-to-DHEA-S ratio and the bioavailability of the precursor at peripheral tissues for local androgen and estrogen synthesis. A man with high SULT2A1 activity converts DHEA to DHEA-S rapidly — which is efficient for storage but may reduce immediate bioavailability at target tissues before de-sulfation occurs.

Why Upstream Steroid Pathway Genetics Matter for Hormone Optimization

The downstream hormone picture — testosterone levels, free vs. bound fractions, DHT, estradiol — is built on the precursor pool that the DHEA and pregnenolone pathway supplies. Several practical implications:

Adrenal androgen contribution: In men, the adrenal glands contribute meaningfully to circulating DHEA, androstenedione, and their downstream conversion products. CYP17A1 17,20-lyase variants that reduce DHEA output lower the adrenal contribution to the total androgen picture — a supply-side variable that serum testosterone testing alone cannot isolate.

Age-related DHEA decline: DHEA-S declines at roughly 2–3% per year after peaking in the mid-20s, making it one of the most reliably measured aging biomarkers in steroid hormone research. The rate of that decline is partly genetically influenced through CYP17A1, HSD3B2, and SULT2A1 variants. Men with genetic profiles favoring efficient DHEA synthesis maintain higher precursor pools at older ages than population averages predict.

Precursor pathway support: When upstream steroid precursors are part of a fertility-preserving androgen modulation strategy — supporting the androgen pathway through precursor-category compounds rather than direct androgens — how efficiently CYP17A1 and HSD3B2 convert that substrate downstream determines the actual yield. Genetic variants affecting enzyme activity shape the output of precursor supplementation in ways that population-average dosing strategies cannot account for individually.

The Pregnenolone-Cortisol Tradeoff: Stress and the Androgen Pathway

Pregnenolone sits at a genuine branch point between sex steroid and glucocorticoid synthesis. When the HPA (hypothalamic-pituitary-adrenal) axis is chronically active under sustained stress, adrenal resources are directed toward cortisol synthesis — via the progesterone → 11-deoxycortisol → cortisol route through CYP11B1 (11-beta-hydroxylase) — competing with the DHEA-producing Δ5 branch for the same pregnenolone substrate and enzyme capacity.

The genetic dimension: the relative activity of CYP17A1's 17,20-lyase step versus CYP11B1 shapes the balance between DHEA production and glucocorticoid synthesis under equivalent adrenal stimulation. Men with genetic profiles favoring higher glucocorticoid synthesis may produce proportionally less DHEA under stress conditions — a variable that a single blood draw at a non-stressed time point cannot capture, but that genetic pathway analysis contextualizes. Understanding this tradeoff helps providers interpret DHEA-S trends over time rather than reading a single value in isolation.

DHEA and Pregnenolone Genetics in the Full Men's Hormone Panel

These upstream pathway genetics are one of 6 Reproductive Health insights the Precision Peptide Genetic Test analyzes as a connected system — part of the broader framework in the Complete Guide to Genetic Men's Hormone Testing:

SHBG — free testosterone availability downstream is influenced by the adrenal androgen contribution the DHEA pathway provides to the total precursor pool. SHBG Genetics: Why Your Free Testosterone Varies covers how SHBG governs how much of that testosterone stays bioavailable.

CYP19A1 — aromatase converts not only testosterone but androstenedione (a direct DHEA downstream metabolite) to estrone. The DHEA pathway feeds aromatase substrate directly, meaning CYP19A1 activity interacts with upstream DHEA production to shape the estrogen picture as well as the androgen one. CYP19A1 and Estrogen Conversion in Men covers this connection.

AR (CAG repeats) — receptor sensitivity determines how the testosterone derived from DHEA conversion is read at the cellular level. Supply and sensitivity are both genetically variable — upstream production and downstream reception must be understood together. Androgen Receptor CAG Repeats: Sensitivity Explained covers the receptor dimension.

SRD5A2 — 5-alpha reductase converts androstenedione-derived testosterone to DHT, meaning DHT output is partly a function of how efficiently the upstream DHEA cascade has supplied the testosterone substrate. SRD5A2 and 5-Alpha Reductase Genetics covers the DHT conversion step.

LHCGR / FSHR — LH-stimulated Leydig cell testosterone production and FSH-stimulated spermatogenesis work in parallel with adrenal DHEA-derived androgens as complementary steroidogenic streams. HPTA Axis Genetics: LH, FSH, and Fertility Preservation covers how the testicular axis genetics interact with the full hormone picture.

Together, these 6 insights trace the male steroid hormone cascade from its upstream source — pregnenolone synthesis from cholesterol — all the way through receptor-level response. DHEA and pregnenolone pathway genetics provide the source-level context that makes the rest of the panel interpretable.

What Your DHEA and Pregnenolone Pathway Results Can and Cannot Tell You

CYP17A1, CYP11A1, HSD3B2, and SULT2A1 variant analysis reveals your genetic baseline for upstream steroid precursor production — how efficiently your adrenal cascade synthesizes, routes, and stores DHEA and pregnenolone toward androgens and estrogens. Results do not measure your current DHEA-S level; that requires blood testing. They do not diagnose any adrenal condition. And they do not predict your response to any specific precursor supplement or hormone protocol.

What they deliver is source-level context: the enzymatic architecture of your upstream steroid cascade, informing how providers interpret DHEA-S trends across time, contextualize adrenal androgen contribution to your total hormone picture, and think about precursor support strategies tailored to your individual genetics. Genetics as a guide, not a guarantee — and as one of 6 Reproductive Health insights within 14 total pathways and 150+ genetic insights, DHEA and pregnenolone pathway genetics provide the upstream layer that makes the downstream picture complete.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand your upstream steroid pathway genetics and where CYP17A1 fits in your hormone profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About DHEA and Pregnenolone Pathway Genetics

What genes govern DHEA and pregnenolone production in men?

CYP11A1 converts cholesterol to pregnenolone — the rate-limiting step in all steroid synthesis. CYP17A1 converts pregnenolone to DHEA. HSD3B converts DHEA toward androstenedione, and SULT2A1 sulfates DHEA to its storage form, DHEA-S. The Precision Peptide Genetic Test analyzes these variants as part of 6 Reproductive Health insights in 14 pathways, 150+ genetic insights.

Why do DHEA levels decline with age and does genetics influence the rate?

DHEA-S declines roughly 2–3% per year after peaking in the mid-20s — one of the most reliably measured aging biomarkers in steroid hormone research. CYP17A1, HSD3B, and SULT2A1 variants influence how efficiently the adrenal cascade produces and stores DHEA. The Precision Peptide Genetic Test contextualizes this genetic baseline as part of the Reproductive Health pathway.

How does CYP17A1 relate to testosterone production?

CYP17A1's 17,20-lyase activity converts pregnenolone to DHEA and androstenedione — the direct precursors feeding testosterone synthesis. Variants reducing this efficiency lower adrenal DHEA output and shrink the precursor pool available for downstream androgen synthesis. The Precision Peptide Genetic Test analyzes CYP17A1 alongside SHBG, CYP19A1, AR, and SRD5A2 for a complete male hormone picture.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.